407 related articles for article (PubMed ID: 34205140)
21. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer.
Mehta K; Kumar A; Kim HI
Biochem Pharmacol; 2010 Dec; 80(12):1921-9. PubMed ID: 20599779
[TBL] [Abstract][Full Text] [Related]
22. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
Agnihotri N; Mehta K
Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
[TBL] [Abstract][Full Text] [Related]
23. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of tissue transglutaminase.
Keillor JW; Apperley KY; Akbar A
Trends Pharmacol Sci; 2015 Jan; 36(1):32-40. PubMed ID: 25500711
[TBL] [Abstract][Full Text] [Related]
25. Identification of DNAJA1 as a novel interacting partner and a substrate of human transglutaminase 2.
Ergülen E; Bécsi B; Csomós I; Fésüs L; Kanchan K
Biochem J; 2016 Nov; 473(21):3889-3901. PubMed ID: 27551108
[TBL] [Abstract][Full Text] [Related]
26. Hyaluronic Acid Interacting Molecules Mediated Crosstalk between Cancer Cells and Microenvironment from Primary Tumour to Distant Metastasis.
Xu Y; Benedikt J; Ye L
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791985
[TBL] [Abstract][Full Text] [Related]
27. In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model.
van der Wildt B; Wilhelmus MMM; Beaino W; Kooijman EJM; Schuit RC; Bol JGJM; Breve JJP; Pasternack R; Lammertsma AA; Windhorst AD; Drukarch B
EJNMMI Res; 2018 May; 8(1):39. PubMed ID: 29802556
[TBL] [Abstract][Full Text] [Related]
28. Transglutaminase 2 maintains a colorectal cancer stem phenotype by regulating epithelial-mesenchymal transition.
Ayinde O; Wang Z; Pinton G; Moro L; Griffin M
Oncotarget; 2019 Jul; 10(44):4556-4569. PubMed ID: 31360304
[TBL] [Abstract][Full Text] [Related]
29. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
Wang X; Yu Z; Zhou Q; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L
Oncotarget; 2016 Feb; 7(6):7066-79. PubMed ID: 26771235
[TBL] [Abstract][Full Text] [Related]
30. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.
Fisher ML; Adhikary G; Xu W; Kerr C; Keillor JW; Eckert RL
Oncotarget; 2015 Aug; 6(24):20525-39. PubMed ID: 25971211
[TBL] [Abstract][Full Text] [Related]
31. Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target.
Eckert RL
Mol Carcinog; 2019 Jun; 58(6):837-853. PubMed ID: 30693974
[TBL] [Abstract][Full Text] [Related]
32. Transglutaminase is a tumor cell and cancer stem cell survival factor.
Eckert RL; Fisher ML; Grun D; Adhikary G; Xu W; Kerr C
Mol Carcinog; 2015 Oct; 54(10):947-58. PubMed ID: 26258961
[TBL] [Abstract][Full Text] [Related]
33. Tissue transglutaminase: from biological glue to cell survival cues.
Mehta K; Fok JY; Mangala LS
Front Biosci; 2006 Jan; 11():173-85. PubMed ID: 16146723
[TBL] [Abstract][Full Text] [Related]
34. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase.
Shao M; Cao L; Shen C; Satpathy M; Chelladurai B; Bigsby RM; Nakshatri H; Matei D
Cancer Res; 2009 Dec; 69(24):9192-201. PubMed ID: 19951993
[TBL] [Abstract][Full Text] [Related]
35. Transglutaminase type 2-dependent selective recruitment of proteins into exosomes under stressful cellular conditions.
Diaz-Hidalgo L; Altuntas S; Rossin F; D'Eletto M; Marsella C; Farrace MG; Falasca L; Antonioli M; Fimia GM; Piacentini M
Biochim Biophys Acta; 2016 Aug; 1863(8):2084-92. PubMed ID: 27169926
[TBL] [Abstract][Full Text] [Related]
36. Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation.
Adhikary G; Grun D; Alexander HR; Friedberg JS; Xu W; Keillor JW; Kandasamy S; Eckert RL
Oncotarget; 2018 Oct; 9(77):34495-34505. PubMed ID: 30349644
[TBL] [Abstract][Full Text] [Related]
37. Feline chronic kidney disease is associated with upregulation of transglutaminase 2: a collagen cross-linking enzyme.
Sánchez-Lara AC; Elliott J; Syme HM; Brown CA; Haylor JL
Vet Pathol; 2015 May; 52(3):513-23. PubMed ID: 25047228
[TBL] [Abstract][Full Text] [Related]
38. Endoplasmic reticulum-resident protein 57 (ERp57) oxidatively inactivates human transglutaminase 2.
Yi MC; Melkonian AV; Ousey JA; Khosla C
J Biol Chem; 2018 Feb; 293(8):2640-2649. PubMed ID: 29305423
[TBL] [Abstract][Full Text] [Related]
39. Tissue transglutaminase, inflammation, and cancer: how intimate is the relationship?
Kumar S; Mehta K
Amino Acids; 2013 Jan; 44(1):81-8. PubMed ID: 22083892
[TBL] [Abstract][Full Text] [Related]
40. Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring.
Fisher M; Jones RA; Huang L; Haylor JL; El Nahas M; Griffin M; Johnson TS
Matrix Biol; 2009 Jan; 28(1):20-31. PubMed ID: 19013523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
